24th Jul 2020 14:33
(Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has initiated a first phase of HMPL-306 study in China for patients with haematological cancer.
The phase one study will consist of two stages, where patients will receive ascending oral doses of HMPL‑306 to determine the maximum tolerated dose or the recommended Phase II dose, the Hong Kong-based company said. The second stage of the study is a dose expansion phase.
The multi-centre study could bring China it's first approved isocitrate dehydrogenase inhibitor, greatly needed as Chi-Med's research indicate an estimated 19,700 new cases of acute myeloid leukaemia were reported in 2018, with cases estimated to reach 24,200 by 2030.
Isocitrate dehydrogenase are enzymes that help to break down nutrients and generate energy for cells. When mutated, isocitrate dehydrogenase creates a molecule that alters the cell's genetic programming and prevents cells from maturing. IDH1 or IDH2 mutations are common genetic alterations in various types of blood and solid tumours.
Shares in Hutchison China MediTech were up 0.4% at 413.00 pence each in London on Friday afternoon.
By Neetika Kurup; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed